New Release – Protembis Announces FDA Approval of its Pivotal Investigational Device Exemption (IDE) Study
Novel Adaptive Superiority Trial Design of ProtEmbo® Cerebral Embolic Protection (CEP) System
Novel Adaptive Superiority Trial Design of ProtEmbo® Cerebral Embolic Protection (CEP) System
Protembis announces the appointment of Professor J. Mocco to Board of Directors
Azin Parhizgar To Chair Protembis’ New Board of Directors
Protembis announces completion of 20 cases in European CE mark study with the ProtEmbo® Cerebral Protection System Enrollment with advanced generation device for complete cerebral protection nearing halfway mark in clinical study in Germany and Poland Aachen, Germany, February 25, 2021 Protembis GmbH, a privately held emerging medical device company, announced today the successful completion … Weiterlesen …
Aachen-based Startup Company Protembis Successfully Closes $ 10 Million Series A Financing
Protembis Achieves ISO 13485:2016 Quality Management System Certification
Protembis announces successful first-in-human use of its ProtEmbo®Cerebral Protection System in European trial
Protembis Initiates Collaboration with German Accelerator Life Sciences for Planned U.S. Expansion
Medical device company Protembis GmbH has closed its seed financing round